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ABSTRACT 
The complex between the macrocyclic ligand DOTA and the metal gadolinium (Gd3+) has been 
used as the contrast agent for the MRI T1 weighed imaging. Mono substitution on the tetraaza ring 
of DOTA ligand results in the formation of the two distinct complexes that are regioisomers of 
each other and they have different contrast efficiency as well as stability. These regioisomers are 
only separated by HPLC. With two bulky substituents on the tetraaza ring, it is expected to increase 
the selectivity of what regioisomers will be formed for each di-substituting pattern since the 
conformation with the least steric hindrance will be favored most to maintain the stability of the 
ring structure. This will simplify the synthesis procedure by removing the separation of the 
different regioisomers. The contrast efficiency and stability of the complexes made from these new 
ligands will also need to be explored. Based on the special characteristics of the DOTA’s tetraaza 
ring, three di-substitution patterns will be studied are 2,8-S,S, 2,9-S,S, and 2,5-S,S. This paper’s 
goal is to report the synthesis progress of these three patterns. The synthesis includes four main 
stages: dibenzyl polypeptide chain, dibenzyl tetra amine chain, dibenzyl tetraaza cyclododecane, 
and dibenzyl DOTA. Cyclization in the third stage is crucial to control the di-substitution patterns. 
The identity of the product in each step was verified by using 1H-NMR and mass spectrometry. 
Pattern 2,9-S,S passed the first two stages and its dibenzyl tetraamine chain needs to be purified 
before entering the cyclization process. Pattern 2,8-S,S could not be built from the N terminal 
(after building the second peptide bonds, the intermediate product had solubility issues.) The first 
peptide bond for the pattern 2,5-S,S is still being built from the N terminal.  
INTRODUCTION 
The use and limitation of DOTA in MRI imaging technique 
MRI imaging has been widely used for the diagnosing purposes in the medical fields because this 
technique does not require the use of radioactive isotopes and provides high spatial resolution [1] 
[2] [3]. Many different scans and contrast levels can be applied until the normal and the abnormal 
parts can be observed [4]. Therefore, the role of contrast agents in MRI imaging is very important. 
Depending on the texture of the examining area that the appropriate scan sequence is selected [4]. 
For T1 weighed imaging, gadolinium based contrast agent (GBCA) is used very often. GCBA is a 
complex of lanthanide metal ion gadolinium (Gd3+.) The most famous ligand for GBCA is the 
macrocyclic DOTA [5] (figure 1.) The function GBCA is to interact with the water molecules in 
the examining area to reduce their protons’ T1 time constants. Those time constants reflect the 
different relaxation of the protons in different environments and they are assigned with different 
color scales. Combining the location and the color scales, the MRI T1 weighed image is formed [6] 
[7]  
The GBCA complex itself is safe for the human body. 
However, if decomplexation happens, the free metal ion 
Gd3+, whose radius is 108pm, can displace the metal ion 
Ca2+ , whose radius is 114pm. Ca2+  participates in many 
biochemical processes of the cells in the human body. 
Gd3+can act as a competitive inhibitor of Ca2+ and thus, 
disturb these processes [8]. That is why there is a 
growing concern about increasing the stability and thus, 
the safety of GBCA. In order to make Gd3+ favor 
staying in the complex, modification on the ligand 
structure is necessary. This research focuses on modifying the macrocyclic (or the tetraaza ring) 
component of DOTA ligand.  
Mono-substitution results stimulated the study of di-substitution 
In the past studies, adding a nitro benzyl group on the tetraaza ring of DOTA affects the ability to 
form complex with Gd3+ of this new ligand (NB-DOTA.) [9] [10] Specifically, when NB-DOTA 
interact with Gd3+, a fixed ratio of two distinct complexes are formed [10]. These complexes are 
regioisomer of each other (figure 2.) Depending on the direction when Gd3+ approaches the ligand 
that corner or side regioisomers will form [10].  These regioisomers have different geometry, 
stability and energy, and thus, they have different contrast efficiency as showed in table 1[11]. The 
most important difference to notice between the two regioisomers is the water residence time (τ
M
) 
which is inversely proportional to the water exchange rate since this parameter reflects the 
interaction between the GBCA and the water molecules. These regioisomers can only be separated 
by HPLC (figure 3.) [10] These fascinating results stimulated the further study on the effect of 
substitution on DOTA’s tetraaza ring. Therefore, di-substitution became the subject in this study. 
 
Figure 1: [GdDOTA]- interacts with a water molecule 
 
If two benzyl substituents are placed on the tetraaza 
ring of DOTA, two trends are expected. First, in order 
to maintain the stability of the ring, the conformation 
having the least steric hindrance will be favored. 
Secondly, the presence of the two bulky benzyl 
groups reduces the macrocyclic ring’s mobility of the 
complex and thus, prevents the conversion between 
the isomer forms due to ring flipping. If these two 
trends are observed, they can support the hypothesis 
that di-substitution can control what type of 
regioisomers will be formed and thus, no additional 
steps to separate the side and corner regioisomers are 
needed since only one type will be formed. The three 
patterns will be studied and their expected 
dominating regioisomers are summarized in figure 4.  
 
Table 1: Fitting Parameters for the NMRD Profiles of the Corner 
and Side Isomers of GdNB-DOTA in Aqueous Solution[11]
 
Figure 2: The tetraaza ring structure of the two regioisomers 
created by NB-DOTA ligand 
A
U
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
0.90
1.00
1.10
1.20
Minutes
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00 16.00 17.00 18.00 19.00 20.00 21.00
Corner 
(75%) 
Side 
(25%) 
Figure 3: The HPLC Chromatogram of the separation of Corner and 
Side [10] 
 
Figure 4: The summary of the three di-substitution patterns on DOTA’s tetraaza ring and their expected complex's regioisomer 
For the pattern 2,8-S,S and 2,5-S,S, the benzyl groups are on the same plane so the only way to 
minimize steric hindrance is to favor conformation having them in the equatorial positions. Once 
the complex is formed, corner regioisomer is more favorable since it has less steric hindrance. For 
the case of pattern 2,9-S,S, both corner and side regioisomers are expected but the specific ratio 
cannot be predicted since the two benzyl groups are located on the different plane of the ring. This 
allows the macrocyclic ring of its complex to have more mobility comparing to the other patterns. 
Developing synthesis strategy to control the desired di-substitution patterns 
The synthesis of these di-substituted DOTA includes four main stages: dibenzyl polypeptide chain, 
dibenzyl tetra amine chain, dibenzyl tetraaza cyclododecane, and dibenzyl DOTA.  From the pure 
simple amino acids and amine, the dibenzyl peptide chain is built by using the peptide synthesis 
techniques. Building the peptide chain is an important stage because it determines the position of 
the benzyl substituents on the tetraaza ring in the future. Cyclization in the third stage is necessary 
since the substituents need to be located on the tetraaza ring before the pendant arms are added. 
However, once the tetraaza ring is closed, the substituents will more likely to be attacked the lone 
pairs of the nitrogen atoms. Those nitrogen spots must be saved for the pendant arms to create the 
desired DOTA derivative forms. Therefore, the position of the benzyl substituents must be defined 
on the precursors of the tetraaza ring. The retro synthesis plan for the three patterns are showed in 
the figure 5 below: 
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Figure 5: The retro synthesis plan for the three proposed patterns 
Cyclization procedure is based on the method developed by Reed and Weisman [12] to synthesize 
cyclen. Figure 6 below summarizes the cyclization process of the pattern 2,9-S,S with R is the 
abbreviation of the benzyl group 
 
Figure 6: The summary of the cyclization process for the pattern 2,9-S,S 
RESULTS AND DISCUSSION 
The progress of pattern 2,8-S,S 
The synthesis progress of pattern 2,8-S,S is summarized in figure 7 below:  
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Figure 7 The summary synthesis progress of the pattern 2,8-S,S 
The polypeptide chain of this pattern (figure 8) could not be built 
from the N terminal in the first attempt. The issue with solubility 
already happened after the first peptide bond was built but it was 
neglected since the intermediate solid product could not dissolve in 
CDCl3, MeOH, H2O or MeCN with some drops of 
iPr2Net but 
DMSO. Using too much DMSO solvent (150mL) during the process 
of building the second peptide bond was a big mistake since it required a lot of heat to vaporize 
DMSO. Increasing the temperature of the water bath too high lead to the unwanted removal of the 
O
ONH2
N
H
H
N
NH2
O
2,8-S,S- polypeptide
Figure 8: 2,8-S,S-dibenzyl 
polypeptide 
 
Boc protection group on the N terminal of Phenylalanine. The product could not be dissolved in 
the available organic solvent, therefore, no 1H-NMR nor mass spectrometry analysis could be 
done. This solid formed complex with Cu2+ and dissolved in the mixture of H2O and MeOH. 
However, the result from the mass spectrometry analysis could not confirm the presence of desired 
product. The fact that this solid could form complex with Cu2+ confirmed that there were peptide 
bond formed (Amide can form complex with Cu2+) but specifically whether they were the desired 
ones or not could not be concluded.  The next step for this pattern will be (a) redo the N terminal 
using a smaller amount of DMSO or develop a mixture of the different solvents that the 
intermediate product can dissolve and (b) trying to build the peptide bonds from the C terminal: 
letting Boc-Phe-OSu reacts with ammonium then remove the Boc group and build the next bond. 
The progress of pattern 2,9-S,S 
The synthesis progress of pattern 2,9-S,S is summarized in figure 9 below: 
 
Figure 9: The summary synthesis progress of the pattern 2,9-S,S 
This pattern is easier to synthesize than the other ones. All the desired peptide bonds were built in 
one step. After removing the Boc protection group, the polypeptide was successfully reduced to 
the desired tetraamine chain. The tetraamine chain is not ready for the cyclization process yet since 
is still in the aqueous layer. The 1H-NMR spectrum of the organic layer did not have the aromatic 
signal from the benzyl substituents. In addition, the signals from the solvent were much stronger 
than the examining compound’s. The protons from the linear chain and the benzyl substituents of 
2,9-S,S-dibenzyl tetraamine showed up  in the 1H-NMR spectrum of the aqueous layer. However, 
this spectrum also contains strong signal from the solvent MeOH. Therefore, the next step will be 
developing a HPLC method to purify 2,9-S,S dibenzyl tetraamine chain. The 1H-NMR spectrum 
and the mass spectrum of this tetraamine chain are showed in figure 10. The molecular weight of 
the target molecule is 326.25 amu. The results from running the mass spec in the positive mode 
(M+H+) has a significant high peak of 327.25 and thus, confirmed the presence of 2,9-S,S-dibenzyl 
tetraamine chain in the aqueous layer.  
 
Figure 10: The mass spectrum (left) and the 1H-NMR spectrum (right) of 2,9-S,S dibenzyl tetraamine 
The progress of pattern 2,5-S,S 
The synthesis progress of pattern 2,5-S,S is summarized in figure 11 below: 
 
Figure 11: The synthesis progress of pattern 2,5-S,S 
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This pattern is still at the stage of making the polypeptide chain which 
is showed in the figure 12. The strategy is to build from the N 
terminal: one side of Ethylene diamine is covered with the Cbz 
protection and the other is left active to build the first peptide bond 
with Boc-Phenylalanine-OSu. However, after putting the Cbz in, the 
product needed to be separated from the matrix. In the first trial, the last NMR spectra did not 
confirm the presence of Ethylene diamine having one protected side.  There might be not enough 
Ethylene diamine. In the contrary, the dry flash column chromatography in the second trial was 
necessary because there was still some unprotected Ethylene diamine (its present was confirmed 
when comparing TLC of fraction 2 with Ethylene diamine in MeOH.)  The three fractions obtained 
from the column are still being analyzed. Specifically, when performing the TLC comparing with 
the solvent MeOH and the mixture of MeOH and Et2O, fraction 2 seems to contain the desired 
product because it had different retention factor than the solvent’s. Fraction 1 had the retention 
factor no different than the solvent. By that time fraction 3 was not dried yet to run TLC. Therefore, 
fraction 2 must be analyzed first. A large amount of MeOH and Et2O was added in fraction 2 in 
attempt to separate the desired product through crystallization. The NMR spectra of crystal from 
fraction 2 and the original fraction 3 in DMSO have not been analyzed yet.  
EXPERIMENTAL PROCEDURE 
The four starting materials for the peptide synthesis in this project are Boc-Glycine-OSu (Boc-
Gly-OSu), L Phenylalanine-OBn (Phe-OBn), Boc-Phenylalanine-OSu (Boc-Phe-OSu), and 
Ethylene diamine. Another goal must be achieved is to see if it is possible to make the desired 
polypeptide chains with a minimum number of the pure, prepared and simple amino acids.  All 
amino acids used in this experiment were purchased from TCI America. Ethylene diamine and the 
other chemicals were purchased from Sigma-Aldrich. The mass spectrometry analysis were 
performed by using the ThermoElectron LTQ-Orbitrap Discovery high resolution mass 
spectrometer with an Accela HPLC system. The H-NMR spectra were collected by using the 
Bruker 400 MHz Avance II and spectrometer with the default probe is 5 mm BBFO. The use of 
the corrosive Ethylene diamine, air sensitive and toxic chemicals TFA, BH3.THF, Benzyl 
ONH2
N
H
H
N
NH2
O
2,5-S,S- polypeptide
Figure 12: 2,5-S,S-dibenzyl 
polypeptide  
 
chloroformate and the operation of the Schlenk line followed the safety instruction of the 
Chemistry Department of the Portland State University.  
Pattern 2,8-S,S 
Phe-OBn (10.3mmol) was mixed with Boc-Gly-OSu (10.5mmol) in the 
solvent containing DCM (100mL) and iPr2Net (10.3 mmol.) The mixture 
was stirred at the room temperature for 2 hours before getting a base wash 
with supersaturated Na2CO3 and then extracted with DCM. After drying 
off the solvent DCM, the intermediate product (5.44g) was collected and 
an NMR analysis in CDCl3 was performed. The first peptide bond (figure 
13) was built. 
This intermediate product was mixed with a solvent containing DCM 
(25mL) and TFA (25mL) in air free condition and stirred for 1 hour at 
35oC. Another round with base wash and extraction with DCM was 
performed. After drying, 6.04 g of solid was collected. This solid could 
not dissolve in CDCl3, MeOH, H2O or MeCN with some drops of 
iPr2Net 
but DMSO. No NMR nor mass spectrometry analysis was performed but 
the expected structure is showed in figure 14. 
The solid was dissolved in the solvent containing DMSO (150mL) 
and iPr2Net (10.3mmol), mixed with Boc-Phe-OSu (10.3 mmol), 
stirred at room temperature for one day. DMSO was removed by 
rotovaping with the temperature increasing gradually from 25oC to 
75 oC. The white oily product could not dissolve in any available 
organic solvents nor the mixture of them. No NMR analysis was 
performed but the expected structure is showed in figure 15. This 
intermediate formed a complex with Cu2+ and this complex dissolved in H2O and MeOH. Mass 
spectrometry analysis on this complex was performed but there was no sign of the expected 
molecule appeared on the mass spectrum. 
 
 
Figure 13: 2,8-S,S pattern 
first peptide bond with Boc 
and OBn protection 
 
Figure 14: 2,8-S,S pattern 
first peptide bond  with  
OBn protection 
 
Figure 15: 2,8-S,S pattern first 
and second peptide bonds with 
Boc and  OBn protection 
 
Pattern 2,9-S,S 
Ethylene diamine (3.30mmol) was mixed with Boc-Phe-OSu 
(6.92mmol) in DCM (100mL) and stirred at room temperature for 
1 hour before getting a base wash with Na2CO3 and extracted with 
DCM to collect the organic layer. This layer was kept at 0oC for 5 
days before decanting the solvent.  1H-NMR in MeOD was 
performed. At this stage, the two desired peptide bonds were 
formed (figure 16.) 
To remove the Boc group, the intermediate product was mixed with 
the solution of 1M acetyl chloride in dried MeOH and stirred in air 
free condition at room temperature for 1 hour. After adding MeOH 
(50mL) and Et2O (100 mL), the sample was stored at 0
oC for 10 
days. After decanting the solvent, 0.7537g of light green yellow 
crystal was collected. 1H-NMR in D2O was performed on the 
sample of this crystal. At this point, the peptide chain (figure 17) was completed. 
This crystal (0.4251g) was mixed with BH3.THF (30 mL) and 
heated at 57oC for 1 day in inert atmospheric condition. When the 
mixture cooled down to room temperature, MeOH (50mL) was 
added by portion before stirring for 1 hour. Small portion of MeOH 
was added until no bubble of H2 was observed. This indicated that 
the Boron complex was deactivated. The solvent was removed. Four rounds of washing the solid 
with MeOH (100mL each time) and removing the solvent were done and the product was an 
orange-brown oil with very uncomfortable fishy smell was collected. This oil was mixed with HCl 
solution (30mL, 1:10 v,v) and heated at 108 oC for 16 hours. KOH tablets were added by portion 
until the pH reached 14. After the extraction with DCM, both aqueous and organic layers were 
saved to analyze.  The solvent was dried off from the organic layer and the 1H-NMR spectrum in 
CDCl3 of this intermediate product was collected. Pure water was added in the aqueous layer until 
the final volume equal to three times of the initial volume. This mixture was kept at -40oC for two 
days before removing frozen solvent by freeze drying. The 1H-NMR spectrum in D2O and the 
Figure 16: 2,9-S,S  dibenzyl poly 
peptide with Boc protection groups 
Figure 17: 2,9-S,S dibenzyl 
polypeptide 
Figure 18: 2,9-S,S dibenzyl tetraamine 
mass spectra in H2O/MeOH of this newly collected solid were obtained. The target molecules 
(figure 18) was found in the aqueous layer. 
Pattern 2,5-S,S 
Two trials with different starting amount of Ethylene diamine and Benzyl chloroformate were 
made as showed in table 2 below: 
Trial Ethylene diamine (mmol) Benzyl chloroformate (mmol) Ratio 
1 28 14 2:1 
2 58 14.5 4:1 
Table 2: The summary amount of the starting materials in two trials 
In both trials, the first goal was to add a Cbz protection group on one end of Ethylene diamine 
(figure 19) 
In trial 1, an air free condition was obtained by using the pressure equalizing 
funnel drop. At 0oC, Ethylene diamine was added in DCM (100mL), then Benzyl 
chloroformate was added and the mixture was stirred for 1 hour before  the 
addition of H2O (15mL).  After extracting and removing the solvent DCM from 
the organic layer, the product was dissolved in CDCl3 to run 
1H-NMR but it was 
not the desired molecule.  
In trial 2, after Ethylene diamine and Benzyl chloroformate got mixing in the 
same condition in the trial 1, the mixture was stirred overnight.  Cu(OH)2CuCO3 (14.5mmol)  in 
H2O (20mL) was slowly added and stirred. When the pH was 12, the organic layer was extracted 
with DCM and dried. 1H-NMR analysis in MeOD was performed. TLC comparing with Ethylene 
diamine was performed. Dry flash column chromatography was performed on the sample with the 
first wash was Et2O and three fractions in MeOH. When all fractions dried, TLC tests comparing 
with MeOH, mixture of MeOH (35%) and Et2O (65%), and Ethylene diamine were performed to 
find the fraction containing the most amount of the product. A significant larger amount of the 
solvent containing MeOH and Et2O (ratio 1:2) was added in the fraction 2. After one day, the 
solvent was decanted to collect the crystalized solid. 1H-NMR in DMSO of the crystalized fraction 
2 and the fraction 3 were performed. 
Figure 19: Ethylene 
diamine with Cbz 
protection to build 
the first peptide 
bond of the 2,5-S,S 
pattern 
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